Welcome to Changzhou Ruiming Pharmaceutical Co.,Ltd

Content

1. Brief Introduction
2. Milestone
3. Management system
4. Personnel
5. Product

1.Brief Introduction

Changzhou Ruiming Pharmaceutical is located at No.1558, Longjiang Bei Road, Changzhou City , Xinbei District China-213127 Chunjiang Town, Jiangsu Province

FEI: 3007086821

DUNS: 528186718

The company was built in 2005 with the investment of RMB 50 millions.

The APIs with high technology, high value added and low pollution are the major target of the company. The design and building of the whole plant meets the GMP requirement.

The total area of company is 25,000m^2, and the green area is more than40**%**.

The plant is partitioned into production area (Synthesis area and clean area), assistant facilities, warehouse and office. The human flow and material flow are separated. There are three buildings for API and intermediates synthesis and drying, and one building for API purification, drying and packaging (cleaning degree: D).

Layout of company



2. Milestone

Time	Development
May 2005	Installed completed
Feb. 2008	Got Drug Manufacturing license and the scope of API. (苏20110162)
Jul. 2009	Got GMP certificate of Propafenone Hydrochloride and Felodipine (K0774)
Apr. 2010	Got DMF number of Tamsulosin Hydrochloride : 23741
July. 2011	Got GMP certificate of Amlodipine Besylate (JS20110008)
Aug. 2011	Got CEP for Amlodipine Besylate (R0-CEP 2008-074-Rev 00)
July .2015	Got renewal GMP certificate of Three API (JS20150443)
July .2015	US FDA site inspection.
July.2016	Got EIR of Tamsulosin Hydrochloride from US FDA（FEI：3007086821）
Aug.2016	Got renewal CEP for Amlodipine Besilate （R1-CEP 2008-074-Rev 00）
May.2017	EDQM site inspection.
Dec.2017	PMDA site inspection.
Sep.2018	US FDA site inspection again.
Aug.2019	CGMP site inspection.
Dec.2022	CGMP site inspection.
Jun. 2023	CGMP site inspection.
Feb.2025	Got CEP certificate of Propafenone Hydrochloride(No. CEP 2023-038 - Rev 00)

EIR of SFDA

FDA U.S. FOOD & DRUG ADMINISTRATION

U.S. Food and Drug Administration
12420 Parklawn Dr. Room 2038
Rockville, MD 20857
www.fda.gov

Via UPS
Return Receipt Requested

October 16, 2018

Mr. Weiming Shi
General Manager
Changzhou Ruiming Pharmaceuticals Co. Ltd
No. 1558 Longjiang Beilu, Xinbei
Changzhou, Jiangsu, 213127 China

Mr. Shi,

The U.S. Food and Drug Administration (FDA) conducted an inspection at Changzhou Ruiming Pharmaceuticals Co. Ltd, FEI 3007086821, located at No. 1558 Longjiang Beilu, Xinbei, Changzhou, Jiangsu, 213127 China from September 10 – 13, 2018. FDA has determined that the inspection classification of this facility is "voluntary action indicated" ("VAI"). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any observations noted on the Form FDA 483 issued at the the conclusion of the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as "official action indicated" ("OAI").

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.


An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.
If you have any questions regarding this letter, you may contact Mr. Kevin Gonzalez via telephone at +1-240-402-0550 or email at Kevin.Gonzalez@fda.hhs.gov.

Sincerely,

Kevin Gonzalez
Branch Director
Division of Foreign Pharmaceutical
Quality Inspections

Renewal CEP of Amlodipine Besilate 1/3



Certification of Substances Department

Certificate of suitability
No. R1-CEP 2008-074 - Rev 01

Name of the substance:
AMLODIPINE BESILATE

Name of holder:
CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD.
No. 1558 Longjiang Bei Road
Changzhou City, Xinbei District
China-213 127 Chunjiang Town, Jiangsu Province

Site(s) of production:
SEE ANNEX 1

THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE
R1-CEP 2008-074 - REV 00

After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **AMLODIPINE BESILATE** no. 1491 of the European Pharmacopoeia, current edition including supplements.

In the last steps of the synthesis ethanol is used as solvent. Its residual content is limited by the test for loss on drying (2.2.32) of the European Pharmacopoeia, with a limit of not more than 0.2%.

No elemental impurity classified in ICH Q3D is intentionally introduced in the manufacture of the substance.

The re-test period of the substance is 36 months if stored in double polyethylene bags, placed in paper drums.

The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

Renewal CEP of Amlodipine Besilate 2/3

28 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice
29 and in accordance with the dossier submitted.

30 Failure to comply with these provisions will render this certificate void.

31 This certificate is renewed from **4 August 2016** according to the provisions of Resolution
32 AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent
33 amendment, and the related guidelines.

34 This certificate has one annex of 1 page.
35 This certificate has:
36 lines.

On behalf of the
Director of EDQM

Strasbourg, 3 March 2022

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD., as holder of the certificate of suitability

R1-CEP 2008-074 - Rev 01 for Amlodipine besilate

hereby authorises .....
(*name of the pharmaceutical company*)


to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (*name of product(s) and marketing number(s), if known*)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (*of the CEP holder*):

Page 2 of 2

Renewal CEP of Amlodipine Besilate 3/3



Certification of Substances Department

Annex 1: Site(s) of production for R1-CEP 2008-074 - Rev 01

Production of Amlodipine besilate:

CHANGZHOU RUIMING PHARMACEUTICAL CO., LTD.
No. 1558 Longjiang Bei Road
Changzhou City, Xinbei District
China-213 127 Chunjiang Town, Jiangsu Province

EDQM Certificate of Suitability
CEP No R1-CEP 2008-074 - Rev 01
Annex 1 Page 1/1

EUGMP certificate of Amlodipine besilate1/2

Finnish Medicines Agency

CERTIFICATE NUMBER: ***FIMEA/2023/006159***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1,2]

Part 1

Issued following an inspection in accordance with
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Finland confirms the following:
The manufacturer: ***Changzhou Ruiming Pharmaceutical Co. Ltd.***
Site address: ***No 1558 Longjiang North Rd, Chunjiang, Xinbei, 213127, China***
OMS Organisation Id. / OMS Location Id.: ***ORG-100025203 / LOC-100034409***

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 8(2) of Regulation (EC) 726/2004.

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2023-11-15***, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2.[3]
- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (http://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

[1] *The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/ECis also applicable to importers.*

[2] *Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

18.4.2024 Siv Lundström

EUGMP certificate of Amlodipine besilate1/2

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection:
AMLODIPINE BESILATE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance:AMLODIPINE BESILATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps: milling, blending etc. 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

4. Other Activities - Active Substances:
The inspection was performed in the frame of the EDQM inspection programme.

2024-04-18

Name and signature of the authorised person of the Competent Authority of Finland
18.4.2024

Siv Lundström
Finnish Medicines Agency
Tel:
Fax:

3.Management system

The company is in charged by General Manager. The organization is built according to GMP, include Quality (QA and QC), Production, Equipment, Materials, Sales, Financial and Admin.

Quality Assurance

Changzhou Ruiming Pharmaceutical Co., Ltd. has built the quality and document system according to ICH and cGMP requirement. It is independent of production in the form of Quality department (include QA and QC). This system is effective to ensure the API meets its established specifications.

The quality assurance department is involved in all quality-related matters. Every responsibility for both quality and production system are described in written.

Product Quality Reviews

Product quality review is performed once a year covering production, process, quality standard (raw material, final product, and intermediate and in-process product), stability study, statistics and analysis of test results, product quality and other related fields such as change control, deviation, register, complaint and so on.

DOCUMENTATION

All documents are prepared, reviewed and issued according to written procedures.

The documentation system is portioned into three parts：

STP-Standard Technical Procedure

SMP-Standard Manage Procedure

SOP- Standard Operation Procedure

Production

The related STP, SMP and SOP on production are prepared according to the requirement of GMP and character of product. The parameter in process is controlled and monitored strictly.

Rejected Raw materials and packaging materials are not used in the production. Rejected intermediates are not used in the next step and Rejected products are not released.

Premises and Equipment

The production area is divided into Synthesis area and Clean Area.

The Synthesis area is about 2700m^2. A relative independent drying room is set for intermediates and crude APIs, respectively. The sale intermediates is dried, blended and packaged in this area.

Main Produce Equipment List

Equipment name	Quantity
Reactor	**50**
Centrifuge	**10**
Dryer	**8**
Mixing machine	**3**
Pulverizer	**4**
Micronizer	**1**

Main Test Instruments List

Test equipment name	Quantity
HPLC	14
GC	3
UV	1
IR	1
Automatic Polarimeter	1
Melting point instrument	1
Karl Fischer moisture meter	1
Microbial limit lab(A&C grade)	1


4.Personnel

The number of employee is 138 now.

There are 44 technologists

Department	Number
Quality (QA and QC and Registration)	24(6/17/1)
Production	40
Materials	5
Equipment	5
Others	58

Organization Chart



5. Product

Tamsulosin Hydrochloride, DMF 023741,FEI：3007086821 For USA and Canada Markets.

Amlodipine Besilate for China and Europe market.

Propafenone Hydrochloride and Felodipine for China market.

Picture of company



Chemical Area



Dryer



Cleaning Corridor



Centrifuge in cleaning area



Dryer for final product



IR



UV



2026-10-21

HPLC


Agilent Technologies
Infinitely better.
Infinitely better.
Infinitely better.
lenovo
ThinkVision

GC



Thanks!